Keros therapeutics to present at the guggenheim smid cap biotech conference

Lexington, mass., jan. 30, 2025 (globe newswire) -- keros therapeutics, inc. (“keros”) (nasdaq: kros), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“tgf-ss”) family of proteins, today announced that keros' chair and chief executive officer jasbir s. seehra, ph.d., will participate in a fireside chat presentation at the guggenheim smid cap biotech conference on thursday, february 6, 2025 at 10:00 a.m. eastern time.
SMID Ratings Summary
SMID Quant Ranking